Bromodomain Factor 5 as a Target for Antileishmanial Drug Discovery

Leishmaniases are a collection of neglected tropical diseases caused by kinetoplastid parasites in the genus Leishmania. Current chemotherapies are severely limited and the need for new antileishmanials is of pressing international importance. Bromodomains are epigenetic reader domains that have shown promising therapeutic potential for cancer therapy and may also present an attractive target to treat parasitic diseases. Here, we investigate Leishmania donovani bromodomain factor 5 (LdBDF5) as a target for antileishmanial drug discovery. LdBDF5 contains pair of bromodomains (BD5.1 and BD5.2) in an N-terminal tandem repeat. We purified recombinant bromodomains of L. donovani BDF5 and determined the structure of BD5.2 by X-ray crystallography. Using a histone peptide microarray and fluorescence polarisation assay, we identified binding interactions of LdBDF5 bromodomains with acetylated peptides derived from histones H2B and H4. In orthogonal biophysical assays including thermal shift assays, fluorescence polarisation and NMR, we showed that BDF5 bromodomains bind to human bromodomain inhibitors SGC-CBP30, bromosporine and I-BRD9, moreover, SGC-CBP30 exhibited activity against Leishmania promastigotes in cell viability assays. These findings exemplify the potential BDF5 holds as a drug target in Leishmania and provide a foundation for the future development of optimised antileishmanial compounds targeting this epigenetic reader protein.

[1]  Michael D. Urbaniak,et al.  Author Correction: Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis , 2023, Nature.

[2]  James A. Watson,et al.  Histone divergence in Trypanosoma brucei results in unique alterations to nucleosome structure , 2023, bioRxiv.

[3]  Chunaram Choudhary,et al.  Acetylation of histone H2B marks active enhancers and predicts CBP/p300 target genes , 2023, Nature Genetics.

[4]  E. Serra,et al.  Deciphering divergent trypanosomatid nuclear complexes by analyzing interactomic datasets with AlphaFold2 and genetic approaches , 2023, bioRxiv.

[5]  A. Cruz,et al.  Life in plastic, it’s fantastic! How Leishmania exploit genome instability to shape gene expression , 2023, Frontiers in Cellular and Infection Microbiology.

[6]  D. Zama,et al.  Visceral Leishmaniasis: Epidemiology, Diagnosis, and Treatment Regimens in Different Geographical Areas with a Focus on Pediatrics , 2022, Microorganisms.

[7]  S. Knapp,et al.  Identification of Histone Peptide Binding Specificity and Small-Molecule Ligands for the TRIM33α and TRIM33β Bromodomains , 2022, ACS chemical biology.

[8]  K. Read,et al.  Anti-trypanosomatid drug discovery: progress and challenges , 2022, Nature reviews. Microbiology.

[9]  J. Mottram,et al.  Bromodomain factor 5 is an essential regulator of transcription in Leishmania , 2022, Nature Communications.

[10]  D. Hassabis,et al.  AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models , 2021, Nucleic Acids Res..

[11]  D. Simola,et al.  Expanding Bromodomain Targeting into Neglected Parasitic Diseases. , 2021, ACS infectious diseases.

[12]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[13]  W. Foulkes,et al.  Achieving clinical success with BET inhibitors as anti-cancer agents , 2021, British Journal of Cancer.

[14]  E. Fischer,et al.  Small-Molecule Approaches to Targeted Protein Degradation , 2021 .

[15]  J. Rappsilber,et al.  A systematic analysis of Trypanosoma brucei chromatin factors identifies novel protein interaction networks associated with sites of transcription initiation and termination , 2021, bioRxiv.

[16]  J. Clos,et al.  Leishmania: Responding to environmental signals and challenges without regulated transcription , 2020, Computational and structural biotechnology journal.

[17]  P. Biggin,et al.  Fragment-Based Identification of Ligands for Bromodomain-Containing Factor 3 of Trypanosoma cruzi. , 2020, ACS infectious diseases.

[18]  P. Grandi,et al.  Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation , 2020, Science.

[19]  S. Conway,et al.  Chemische Epigenetik: der Einfluss chemischer und chemo‐biologischer Techniken auf die Zielstruktur‐Validierung von Bromodomänen , 2019, Angewandte Chemie.

[20]  Jean-Philippe Lambert,et al.  Emerging tools to investigate bromodomain functions. , 2019, Methods.

[21]  R. Sims,et al.  Bromodomains: a new target class for drug development , 2019, Nature Reviews Drug Discovery.

[22]  Juan A. Bueren-Calabuig,et al.  Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition , 2019, Proceedings of the National Academy of Sciences.

[23]  S. Conway,et al.  Small molecules as tools to study the chemical epigenetics of lysine acetylation. , 2018, Current opinion in chemical biology.

[24]  Robert J. Young,et al.  The role and impact of high throughput biomimetic measurements in drug discovery , 2018, ADMET and DMPK.

[25]  Fei Long,et al.  Overview of refinement procedures within REFMAC5: utilizing data from different sources , 2018, Acta crystallographica. Section D, Structural biology.

[26]  S. Liao,et al.  Recognition of hyperacetylated N-terminus of H2AZ by TbBDF2 from Trypanosoma brucei. , 2017, The Biochemical journal.

[27]  A. Yadav,et al.  Cell cycle stage-specific transcriptional activation of cyclins mediated by HAT2-dependent H4K10 acetylation of promoters in Leishmania donovani , 2017, PLoS pathogens.

[28]  K. Gull,et al.  Shape, form, function and Leishmania pathogenicity: from textbook descriptions to biological understanding , 2017, Open Biology.

[29]  M. Khan,et al.  HAT2 mediates histone H4K4 acetylation and affects micrococcal nuclease sensitivity of chromatin in Leishmania donovani , 2017, PloS one.

[30]  Ian H. Gilbert,et al.  Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need , 2017, Nature Reviews Microbiology.

[31]  Chunlin Yang,et al.  Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development , 2017, Microbiology and Molecular Biology Reviews.

[32]  P. Filippakopoulos,et al.  Functions of bromodomain-containing proteins and their roles in homeostasis and cancer , 2017, Nature Reviews Molecular Cell Biology.

[33]  A. Gingras,et al.  Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia , 2016, Science Advances.

[34]  R. Prinjha,et al.  Clinical progress and pharmacology of small molecule bromodomain inhibitors. , 2016, Current opinion in chemical biology.

[35]  T. Heightman,et al.  Isoxazole‐Derived Amino Acids are Bromodomain‐Binding Acetyl‐Lysine Mimics: Incorporation into Histone H4 Peptides and Histone H3 , 2016, Angewandte Chemie.

[36]  E. Serra,et al.  Overexpression of bromodomain factor 3 in Trypanosoma cruzi (TcBDF3) affects differentiation of the parasite and protects it against bromodomain inhibitors , 2016, The FEBS journal.

[37]  Xiaodong Huang,et al.  Drugging the undruggables: exploring the ubiquitin system for drug development , 2016, Cell Research.

[38]  Andrew J. Bannister,et al.  Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. , 2016, Journal of medicinal chemistry.

[39]  F. Papavasiliou,et al.  Bromodomain Proteins Contribute to Maintenance of Bloodstream Form Stage Identity in the African Trypanosome , 2015, PLoS biology.

[40]  S. Saha,et al.  HAT3-mediated acetylation of PCNA precedes PCNA monoubiquitination following exposure to UV radiation in Leishmania donovani , 2015, Nucleic acids research.

[41]  M. Höss,et al.  Small molecule inhibitors of bromodomain-acetyl-lysine interactions. , 2015, ACS chemical biology.

[42]  S. Knapp,et al.  Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains , 2014, Journal of the American Chemical Society.

[43]  S. Knapp,et al.  Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands , 2013, Journal of medicinal chemistry.

[44]  Michèle N Schulz,et al.  MTSA--a Matlab program to fit thermal shift data. , 2013, Analytical biochemistry.

[45]  P. Saha,et al.  The histone acetyl transferase LdHAT1 from Leishmania donovani is regulated by S-phase cell cycle kinase. , 2012, FEMS microbiology letters.

[46]  S. Knapp,et al.  Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. , 2012, Journal of medicinal chemistry.

[47]  Stefan Knapp,et al.  The bromodomain interaction module , 2012, FEBS letters.

[48]  S. Conway.  Bromodomains: are readers right for epigenetic therapy? , 2012, ACS medicinal chemistry letters.

[49]  C. Bountra,et al.  Epigenetic protein families: a new frontier for drug discovery , 2012, Nature Reviews Drug Discovery.

[50]  A. Gingras,et al.  Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.

[51]  S. Saha,et al.  Histone H4 lysine 14 acetylation in Leishmania donovani is mediated by the MYST-family protein HAT4. , 2012, Microbiology.

[52]  Stefan Knapp,et al.  Bromodomains as therapeutic targets , 2011, Expert Reviews in Molecular Medicine.

[53]  Darren V S Green,et al.  Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. , 2011, Drug discovery today.

[54]  S. Knapp,et al.  3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands , 2011, Journal of medicinal chemistry.

[55]  Andrés M. Castillo,et al.  Fast and accurate algorithm for the simulation of NMR spectra of large spin systems. , 2011, Journal of magnetic resonance.

[56]  S. McNicholas,et al.  Presenting your structures: the CCP4mg molecular-graphics software , 2011, Acta crystallographica. Section D, Biological crystallography.

[57]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[58]  Graeme Winter,et al.  xia2: an expert system for macromolecular crystallography data reduction , 2010 .

[59]  David Fenyo,et al.  Four histone variants mark the boundaries of polycistronic transcription units in Trypanosoma brucei. , 2009, Genes & development.

[60]  P. Myler,et al.  Histone acetylations mark origins of polycistronic transcription in Leishmania major , 2009, BMC Genomics.

[61]  Michael Q. Zhang,et al.  Combinatorial patterns of histone acetylations and methylations in the human genome , 2008, Nature Genetics.

[62]  Luc Patiny,et al.  www.nmrdb.org: Resurrecting and processing NMR spectra on-line , 2008 .

[63]  G. Cross,et al.  Histone modifications in Trypanosoma brucei. , 2007, Molecular and biochemical parasitology.

[64]  K. Henrick,et al.  Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.

[65]  B. Cairns,et al.  Autoregulation of the rsc4 tandem bromodomain by gcn5 acetylation. , 2007, Molecular cell.

[66]  S. Mujtaba,et al.  Structure and acetyl-lysine recognition of the bromodomain , 2007, Oncogene.

[67]  G. Fogliatto,et al.  WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability , 2001, Journal of biomolecular NMR.

[68]  M. Sundström,et al.  Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water* , 2000, Journal of biomolecular NMR.

[69]  R. Tjian,et al.  Structure and function of a human TAFII250 double bromodomain module. , 2000, Science.

[70]  Bernd Meyer,et al.  Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy. , 1999, Angewandte Chemie.

[71]  C. Bevan,et al.  Chromatographic Hydrophobicity Index by Fast-Gradient RP-HPLC:  A High-Throughput Alternative to log P/log D. , 1997, Analytical chemistry.

[72]  S. Meiboom,et al.  Modified Spin‐Echo Method for Measuring Nuclear Relaxation Times , 1958 .

[73]  E. Purcell,et al.  Effects of Diffusion on Free Precession in Nuclear Magnetic Resonance Experiments , 1954 .

[74]  V. Jain,et al.  Molecular targets and pathways for the treatment of visceral leishmaniasis. , 2018, Drug discovery today.

[75]  Alexei Vagin,et al.  Molecular replacement with MOLREP. , 2010, Acta crystallographica. Section D, Biological crystallography.

[76]  F. Quiocho,et al.  Multipurpose MRG domain involved in cell senescence and proliferation exhibits structural homology to a DNA-interacting domain. , 2006, Structure.

[77]  Xinyi Huang,et al.  Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. , 2003, Journal of biomolecular screening.